Stout performed buy-side due diligence, including both financial and tax diligence, on behalf of a global leader in neuroscience in connection with its acquisition of a provider of therapies and medication used for the treatment of Major Depressive Disorder (MDD) and other mental health conditions.

Our Healthcare Financial Due Diligence team conducted a comprehensive quality-of-earnings analysis, detailed net working capital procedures, and a debt and debt-like obligations analysis. Throughout the diligence process, Stout delivered critical insights and worked in close partnership with both the client and the company’s board of directors, providing ongoing support on key transaction matters.

Our Tax Due Diligence team performed comprehensive tax due diligence and tax modeling, including analyzing the tax implications of the proposed transaction structure on the target’s U.S. and foreign tax attributes.

In addition, our Valuation Advisory and Accounting & Reporting Advisory teams prepared the opening balance sheet, which included the valuation of intangible assets.